All In Biotech

Drug Trial Radar · NCT01746420

Phase II Study of the Effects of rhPDGF-BB Injection on Lateral Epicondylitis

A Phase II Randomized, Single Ascending Dose, Double-blinded, Placebo Controlled, Multi-center Study of the Effects of rhPDGF-BB Injection on Lateral Epicondylitis

Last checked: Nov 20, 2026Latest source record: Jul 2, 2019 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 100 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

100

Actual

Start

Dec 12, 2012

Primary completion

Oct 21, 2014

Study completion Oct 21, 2014

Sponsor

Lead sponsor
BioMimetic TherapeuticsIndustry
Sponsor type
Industry
First posted
Dec 11, 2012

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
Who can join
All sexes, from 21 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to determine whether recombinant human platelet-derived growth factor (rhPDGF-BB) Injection is effective in the treatment of lateral epicondylitis (tennis elbow).

Conditions

  • Lateral Epicondylitis

Interventions

  • rhPDGF-BB InjectionDrug

    Comparison of placebo control (0 mg rhPDGF-BB) and different dosages (0.45, 0.75, 1.5, and 3.0 mg) of rhPDGF-BB Injection administered through a one-time injection

  • PlaceboDrug

    sodium acetate buffer (0 mg rhPDGF-BB)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Elbow Pain Assessments (VAS), Treated SubjectsTime frame: Baseline, 2, 4, 8, 12, and 24 weeks
  2. Disabilities of the Arm, Shoulder and Hand (DASH), Treated SubjectsTime frame: Baseline, 4, 8, 12, and 24 weeks
  3. Total Score Patient Rated Tennis Elbow Evaluation (PRTEE), All Treated SubjectsTime frame: Baseline, 4, 8, 12, and 24 weeks
  4. Grip Strength Test, All Treated SubjectsTime frame: Baseline, 4, 8, 12, and 24 weeks
  5. Maximum Grip Strength, Treated SubjectsTime frame: Baseline, 4, 8, 12, and 24 weeks

Locations

6 sites in 1 country. Site status is shown where the registry gives one.

  • Arizona Research Center

    Phoenix, Arizona

  • Tucson Orthopaedic Institute

    Tucson, Arizona

  • NEA Baptist Clinic

    Jonesboro, Arkansas

  • Coastal Orthopedics & Sports Medicine

    Bradenton, Florida

  • Foundation for Orthopaedic Research and Education

    Tampa, Florida

  • OrthoCarolina

    Charlotte, North Carolina

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.